These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
152 related articles for article (PubMed ID: 11830514)
21. p130Cas as a new regulator of mammary epithelial cell proliferation, survival, and HER2-neu oncogene-dependent breast tumorigenesis. Cabodi S; Tinnirello A; Di Stefano P; BisarĂ² B; Ambrosino E; Castellano I; Sapino A; Arisio R; Cavallo F; Forni G; Glukhova M; Silengo L; Altruda F; Turco E; Tarone G; Defilippi P Cancer Res; 2006 May; 66(9):4672-80. PubMed ID: 16651418 [TBL] [Abstract][Full Text] [Related]
22. Epigallocatechin gallate inhibits phorbol ester-induced activation of NF-kappa B and CREB in mouse skin: role of p38 MAPK. Kundu JK; Surh YJ Ann N Y Acad Sci; 2007 Jan; 1095():504-12. PubMed ID: 17404063 [TBL] [Abstract][Full Text] [Related]
23. Her-2/neu overexpression induces NF-kappaB via a PI3-kinase/Akt pathway involving calpain-mediated degradation of IkappaB-alpha that can be inhibited by the tumor suppressor PTEN. Pianetti S; Arsura M; Romieu-Mourez R; Coffey RJ; Sonenshein GE Oncogene; 2001 Mar; 20(11):1287-99. PubMed ID: 11313873 [TBL] [Abstract][Full Text] [Related]
24. Mechanism of action of (-)-epigallocatechin-3-gallate: auto-oxidation-dependent inactivation of epidermal growth factor receptor and direct effects on growth inhibition in human esophageal cancer KYSE 150 cells. Hou Z; Sang S; You H; Lee MJ; Hong J; Chin KV; Yang CS Cancer Res; 2005 Sep; 65(17):8049-56. PubMed ID: 16140980 [TBL] [Abstract][Full Text] [Related]
25. The green tea catechins, (-)-Epigallocatechin-3-gallate (EGCG) and (-)-Epicatechin-3-gallate (ECG), inhibit HGF/Met signaling in immortalized and tumorigenic breast epithelial cells. Bigelow RL; Cardelli JA Oncogene; 2006 Mar; 25(13):1922-30. PubMed ID: 16449979 [TBL] [Abstract][Full Text] [Related]
26. A component of green tea, (-)-epigallocatechin-3-gallate, promotes apoptosis in T24 human bladder cancer cells via modulation of the PI3K/Akt pathway and Bcl-2 family proteins. Qin J; Xie LP; Zheng XY; Wang YB; Bai Y; Shen HF; Li LC; Dahiya R Biochem Biophys Res Commun; 2007 Mar; 354(4):852-7. PubMed ID: 17266926 [TBL] [Abstract][Full Text] [Related]
27. (-)-Epigallocatechin-3-gallate promotes pro-matrix metalloproteinase-7 production via activation of the JNK1/2 pathway in HT-29 human colorectal cancer cells. Kim M; Murakami A; Kawabata K; Ohigashi H Carcinogenesis; 2005 Sep; 26(9):1553-62. PubMed ID: 15860507 [TBL] [Abstract][Full Text] [Related]
28. Epigallocatechin-3-Gallate suppresses early stage, but not late stage prostate cancer in TRAMP mice: mechanisms of action. Harper CE; Patel BB; Wang J; Eltoum IA; Lamartiniere CA Prostate; 2007 Oct; 67(14):1576-89. PubMed ID: 17705241 [TBL] [Abstract][Full Text] [Related]
29. Celecoxib, a selective cyclooxygenase 2 inhibitor, protects against human epidermal growth factor receptor 2 (HER-2)/neu-induced breast cancer. Howe LR; Subbaramaiah K; Patel J; Masferrer JL; Deora A; Hudis C; Thaler HT; Muller WJ; Du B; Brown AM; Dannenberg AJ Cancer Res; 2002 Oct; 62(19):5405-7. PubMed ID: 12359744 [TBL] [Abstract][Full Text] [Related]
30. Synergistic inhibition with a dual epidermal growth factor receptor/HER-2/neu tyrosine kinase inhibitor and a disintegrin and metalloprotease inhibitor. Witters L; Scherle P; Friedman S; Fridman J; Caulder E; Newton R; Lipton A Cancer Res; 2008 Sep; 68(17):7083-9. PubMed ID: 18757423 [TBL] [Abstract][Full Text] [Related]
31. Mechanisms of tumor regression and resistance to estrogen deprivation and fulvestrant in a model of estrogen receptor-positive, HER-2/neu-positive breast cancer. Massarweh S; Osborne CK; Jiang S; Wakeling AE; Rimawi M; Mohsin SK; Hilsenbeck S; Schiff R Cancer Res; 2006 Aug; 66(16):8266-73. PubMed ID: 16912207 [TBL] [Abstract][Full Text] [Related]
32. Oral consumption of green tea polyphenols inhibits insulin-like growth factor-I-induced signaling in an autochthonous mouse model of prostate cancer. Adhami VM; Siddiqui IA; Ahmad N; Gupta S; Mukhtar H Cancer Res; 2004 Dec; 64(23):8715-22. PubMed ID: 15574782 [TBL] [Abstract][Full Text] [Related]
33. Basic science of HER-2/neu: a review. Hung MC; Lau YK Semin Oncol; 1999 Aug; 26(4 Suppl 12):51-9. PubMed ID: 10482194 [TBL] [Abstract][Full Text] [Related]
34. Epigallocatechin gallate (EGCG), a major component of green tea, is a dual phosphoinositide-3-kinase/mTOR inhibitor. Van Aller GS; Carson JD; Tang W; Peng H; Zhao L; Copeland RA; Tummino PJ; Luo L Biochem Biophys Res Commun; 2011 Mar; 406(2):194-9. PubMed ID: 21300025 [TBL] [Abstract][Full Text] [Related]
35. Involvement of tyrosine phosphorylation of p185(c-erbB2/neu) in tumorigenicity induced by X-rays and the neu oncogene in human breast epithelial cells. Kang KS; Sun W; Nomata K; Morita I; Cruz A; Liu CJ; Trosko JE; Chang CC Mol Carcinog; 1998 Apr; 21(4):225-33. PubMed ID: 9585252 [TBL] [Abstract][Full Text] [Related]
36. (-)-Epigallocatechin gallate and polyphenon E inhibit growth and activation of the epidermal growth factor receptor and human epidermal growth factor receptor-2 signaling pathways in human colon cancer cells. Shimizu M; Deguchi A; Lim JT; Moriwaki H; Kopelovich L; Weinstein IB Clin Cancer Res; 2005 Apr; 11(7):2735-46. PubMed ID: 15814656 [TBL] [Abstract][Full Text] [Related]
37. Cancer chemoprevention with green tea catechins by targeting receptor tyrosine kinases. Shimizu M; Adachi S; Masuda M; Kozawa O; Moriwaki H Mol Nutr Food Res; 2011 Jun; 55(6):832-43. PubMed ID: 21538846 [TBL] [Abstract][Full Text] [Related]
38. HER-2/neu signal transduction in human breast and ovarian cancer. Reese DM; Slamon DJ Stem Cells; 1997; 15(1):1-8. PubMed ID: 9007217 [TBL] [Abstract][Full Text] [Related]
39. Trastuzumab-resistant HER2-driven breast cancer cells are sensitive to epigallocatechin-3 gallate. Eddy SF; Kane SE; Sonenshein GE Cancer Res; 2007 Oct; 67(19):9018-23. PubMed ID: 17909003 [TBL] [Abstract][Full Text] [Related]
40. The polyphenol epigallocatechin-3-gallate affects lipid rafts to block activation of the c-Met receptor in prostate cancer cells. Duhon D; Bigelow RL; Coleman DT; Steffan JJ; Yu C; Langston W; Kevil CG; Cardelli JA Mol Carcinog; 2010 Aug; 49(8):739-49. PubMed ID: 20623641 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]